Replacement of pancreatic β-cells through deceased donor islet transplantation is a proven therapy for preventing recurrent life-threatening hypoglycemia in type 1 diabetes. Although near-normal glucose levels and insulin independence can be maintained for many years following successful islet transplantation, restoration of normal functional β-cell mass has remained elusive. It has recently been proposed that dedifferentiation/plasticity towards other endocrine phenotypes may play an important role in stress-induced β-cell dysfunction in type 2 diabetes. Here we report loss of end-differentiated β-cell phenotype in 2 intraportal islet allotransplant recipients.
Replacement of pancreatic β-cells through deceased donor islet transplantation is a proven therapy for preventing recurrent life-threatening hypoglycemia in type 1 diabetes. Although near-normal glucose levels and insulin independence can be maintained for many years following successful islet transplantation, restoration of normal functional β-cell mass has remained elusive. It has recently been proposed that dedifferentiation/plasticity towards other endocrine phenotypes may play an important role in stress-induced β-cell dysfunction in type 2 diabetes. Here we report loss of end-differentiated β-cell phenotype in 2 intraportal islet allotransplant recipients.
Despite excellent graft function and sustained insulin independence, all examined insulin-positive cells had lost expression of the end-differentiation marker, urocortin-3, or appeared to co-express the α-cell marker, glucagon. In contrast, no insulin + / urocortin-3 − cells were seen in nondiabetic deceased donor control pancreatic islets.
Loss of end-differentiated phenotype may facilitate β-cell survival during the stresses associated with islet isolation and culture, in addition to sustained hypoxia following engraftment. As further refinements in islet isolation and culture are made in parallel with exploration of alternative β-cell sources, graft sites, and ultimately fully vascularized bioengineered insulin-secreting microtissues, differentiation status immunostaining provides a novel tool to assess whether fully mature β-cell phenotype has been maintained.
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| INTRODUCTION
Following reproducible attainment of insulin independence through the Edmonton protocol, 1 islet transplantation has become an established therapy for prevention of recurrent life-threatening severe hypoglycemia in type 1 diabetes. 2 Although optimal islet grafts can restore nondiabetic glucose levels without adjuvant glucose-lowering therapy, detailed metabolic testing has revealed incomplete restoration of normal functional β-cell mass. 3 This is in contrast to vascularized whole pancreas transplant where normalization of β-cell secretory capacity has been confirmed. 4 During pancreas development, co-expression of insulin and the peptide hormone urocortin-3 is a phenotypic marker of full β-cell maturation.
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Maintenance of β-cell urocortin-3 expression is required for physiological regulation of insulin secretion, with urocortin-3 null mice having deficient insulin secretion during periods of high glucose. β-cell dysfunction, defined by loss of mature end-differentiated phenotypic markers, including urocortin-3, 7 and expression of non-β-cell proteins, including glucagon, 8 has recently been postulated as an important contributor to impaired insulin secretion in type 2 diabetes. 9, 10 We report abnormal β-cell phenotypes in 2 islet transplant recipients despite excellent graft function. antibodies. Co-expression of insulin/urocortin-3 and insulin/glucagon was confirmed by confocal microscopy Z-stack analysis.
| METHODS

| CASE REPORTS
Patient 1 was a 36-year-old woman with type 1 diabetes of 27 years' duration who died following a cerebral hemorrhage 13 years after a single percutaneous infusion of isolated pancreatic islets pooled from 2 deceased donors. 11 Islet transplantation was undertaken for recurrent life-threatening severe hypoglycemia with poor HbA1c (11.2%). 
| RESULTS
| Histological analysis of transplanted islets
In addition to loss of end-differentiation, endocrine cell plasticity
was demonstrated by cells appearing to co-express insulin and glucagon in transplanted islets from both patients (Figure 2 , 3F-H) with colocalization within single cells supported by spectral plot ( Figure 3I ) and Z-stack confocal microscopy (Supplementary Figure S2) . Insulin/glucagon co-expressing cells were identified in all examined islets (>10 per donor).
| DISCUSSION
We have demonstrated immunofluorescence staining phenotypes indicating loss of β-cell end-differentiation in islets transplanted into the portal vein despite stable engraftment and long-term maintenance of normoglycemia.
Metabolic outcomes after intrahepatic islet transplantation continue to improve, and this procedure can now reproducibly deliver virtually normal overall glycemia in tandem with absolute prevention of significant hypoglycemia. 12 Nevertheless, complete normalization of stimulated insulin and C-peptide secretion has remained elusive. 3 Loss of end-differentiated β-cell phenotype may provide at least partial explanation for subtle functional impairment, despite stable engraftment of sufficient β-cell mass to prevent hyperglycemia.
Urocortin-3 expression has been used to identify mature, fully functional β-cells during pancreas development 5 and is expressed at approximately equal levels in α-and β-cells in nondiabetic adult human pancreas. 13 Absence of detectable β-cell urocortin-3 staining in all transplanted islets examined in the current study provides evidence for loss of end-differentiated phenotype despite maintained insulin expression and near-normoglycemia. Loss of urocortin-3 has been reported in human β-cells in association with hyperglycemia in type 2 diabetes.
7,13
It has been proposed that urocortin-3 loss is an adaptive response to β-cell stress/damage, enabling the damaged β-cell to maintain insulin secretion without negative feedback inhibition through urocortin-3-mediated δ-cell somatostatin secretion. 13 Further mechanistic studies are required to determine whether adaptation of β-cells to acute stress evidenced by markers of dedifferentiation including urocortin-3 loss is a direct cause of imperfect glucose control through impaired insulin secretion, or whether phenotypic changes are a reactive response to β-cell dysfunction primarily driven by other mechanisms.
Further evidence for a phenotypic shift in intrahepatic transplanted islets was provided by identification of insulin and glucagon co-expressing cells. Each hormone appeared to be localized to different regions of the cytoplasm without incontrovertible direct overlay.
In addition to confocal microscopy Z-stack imaging, spectral analysis supported the presence of bi-hormonal cells. It has been suggested that β-cell plasticity, leading to cells co-expressing insulin and glucagon, may contribute to abnormal glucagon secretion in type 2 diabetes. 9 Following islet transplantation, glucagon secretion in response to hypoglycemia remains impaired, even following replacement of nearnormal pancreatic β-cell mass.
14 Whether β-cell plasticity, with the presence of cells expressing and secreting both insulin and glucagon, plays a role in this residual abnormality of transplanted islet function requires further study.
In the current case reports, β-cell pathology was not associated with decreasing functional β-cell mass over time or with high glucose.
Amyloid deposition has been reported following intrahepatic islet transplantation, in association with failing grafts and elevated blood glucose levels. 15 We have previously reported near absence of amyloid deposits around islets from Patient 1, 16 in keeping with absence of ongoing β-cell stress due to maintained normoglycemia without evidence of attrition in islet function over time.
Loss of end-differentiated phenotype may facilitate β-cell survival during the ex vivo stresses associated with islet isolation and culture, in addition to sustained hypoxia following engraftment, due to peripheral as opposed to central islet revascularization as reported by ourselves in Patient 1 17 and by others. 18 We have confirmed that islets remain in or at the periphery of the portal tracts at the portal-parenchymal interface. Additional peri-and intra-islet microvasculature may reflect neovascularization from the hepatic artery. 17 Alternatively, the periislet microvasculature could correspond to dilated collateral venules associated with portal venopathy following intraportal islet infusion.
A limitation of this study is the inability to absolutely quantify num- 
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F restoring entirely normal islet mass and function. 18 Evaluation of differentiation status through immunostaining co-localization protocols provides a novel tool to assess whether fully mature β-cell phenotype has been maintained without dedifferentiation/ plasticity following islet and isolated β-cell transplantation. 
